INDe sgRNAs For Preclinical Safety, Toxicity, And Efficacy Studies

Move into the next phase of your CRISPR-based therapeutic development with confidence using IND-enabling (INDe) sgRNAs. INDe sgRNAs are designed specifically for preclinical safety, toxicity, and efficacy studies where the use of high quality sgRNAs with increased quality oversight and documentation can enable a successful IND submission. Synthego's INDe sgRNAs allow you to seamlessly transition from discovery to delivery with higher purity specifications than standard RUO sgRNAs.

Download this Brochure below and check out the rest of Synthego's Preclinical Resource Collection.

• Discovery To Clinic: CRISPR-Based Therapies And Diagnostics
• CRISPR Cell And Gene Therapies: Key Challenges In Clinical Development
• CRISPR Clinical Trials And Regulatory Approval Of CRISPR Therapy Drugs